747 – Brain-derived neurotrophic factor and b-cell lymphoma leukemia-2 plasma levels in patients with subsyndromal symptomatic depression - 09/07/13
Résumé |
Objective |
To explore the relationship between brain-derived neurotrophic factor (BDNF) and B-cell lymphoma Leukemia-2 (Bcl-2) plasma levels in subsyndromal symptomatic depression (SSD) patients.
Methods |
In this case-control study, Enzyme-Linked Immunosorbnent Assay (ELISA) method was used to analysed the differences of BDNF plasma levels between SSD group (n=42) and healthy controls (n=51). At the same time Hamilton Depression Rating Scale-17(HAMD17) were assessed the patients'severity.
Result |
There were significant difference of BDNF plasma levels between SSD group (medium 2.97ng/ml)and healthy group (medium 3.71ng/ml, z=-2.94, P0.003). Furthermore, BDNF plasma levels in SSD patients were associated with Hamilton score (r -0.53, P <0.001). Plasma Bcl-2 levels were not different between SSD group (medium 4951U/ml) and health controls (medium 5574U/ml) (z =-1.71, P =0.09); and plasma Bcl-2 levels in SSD group were not associated with Hamilton score (r-0.10, P0.34).
Conclusion |
The study suggested that the decreased BDNF plasma levels were related with the pathophysiology of SSD and it might reflect the severity of disorder.
Le texte complet de cet article est disponible en PDF.Vol 28 - N° S1
P. 1 - 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?